<DOC>
	<DOCNO>NCT02123433</DOCNO>
	<brief_summary>S. pneumoniae frequently isolate nasal swab healthy subject , also cause severe disease ( pneumonia , bacteraemia , meningitis sepsis ) .HIV-infected subject sensitive invasive disease recurrent infection general population . Nasal carriage main pathogenetic feature invasive disease : bacteraemia frequent carrier , HIV+ patient constantly colonize pneumococcal strain nasopharyngeal isolate feature similar subsequent invasive strain . A 23-valent polysaccharide vaccine ( PPV23 ) long available recommend HIV+ population prophylaxis invasive disease . Studies regard efficacy PPV23 HIV+ controversial highlight immune response induce PPV23 HIV+ poor hyporesponsiveness repeat polysaccaridic antigen stimulation occur . Moreover , PPV23 seem affect pneumococcal carriage status could lead emergence non-vaccine serotypes . The conjugation pneumococcal capsular polysaccharide carrier proteins result improve T-cell dependent immune response , characterize increase antibody concentration induction T B memory cell , demonstrate high efficacy child . A heptavalent vaccine conjugate diphtheria toxoid ( PCV7 ) approve Europe since 2001 effective reduce incidence invasive disease vaccine serotypes ( 4 , 6B , 9V , 14 , 18C , 19F , 23F ) , child adult , due effect herd immunity . A PCV13 formulation recently develop , cover PCV7 serotypes plus 1 , 3 , 5 , 6A , 7F 19A . PCV13 reveal safety profile PCV7 pediatric patient , main target conjugate vaccine licensure . Some trial show well antibody response term quantity quality HIV + adult use PCV7 compare PPV23 . However data unequivocally confirm study use PCV7 alone combination PPV23 . The first trial PCV13 use adult show even well response compare PPV23 , safety tolerability similar PCV7 . PCV13 HIV+ adult promise candidate prophylactic measure pneumococcal infection . The purpose study evaluate serological response prevalence nasopharyngeal colonization S. pneumoniae HIV+ non-hospitalized adult , follow vaccination 2 dos PCV13 .</brief_summary>
	<brief_title>Serological Response Antipneumococcal Vaccination Impact Streptococcus Pneumoniae Nasal Carriage HIV Adults</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>&gt; 18 year old obtain informed consent outpatient CD4 ≥200 cells/µl last two evaluation T0 &gt; 65 year old presence acute infectious disease antibiotic therapy ( ongoing previous &lt; = 7 day ) previous PPV23 PCV7 vaccination Pregnancy Current immunomodulatory therapy Immunosuppression HIV relate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>HIV</keyword>
	<keyword>Streptococcus pneumoniae</keyword>
	<keyword>13-valent conjugate pneumococcal vaccine</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Immunological Response</keyword>
	<keyword>Pneumococcal Carriage</keyword>
</DOC>